Genoox

Company Overview

Snapshot

Founded in March 2014 by Moshe Einhorn, Genoox operates with 51–200 employees. The company has raised $20 million across 6 funding rounds from 9 investors. In May 2025, Genoox was acquired by Qiagen.

Business overview

Genoox is a healthcare and technology company focused on enhancing the accessibility of clinical genetic sequencing. The company provides a cloud-based advanced framework, including purpose-built applications, to manage the entire genetic sequencing process. Its AI-driven product, Franklin, integrates data from published literature and public databases, utilizing machine learning to derive prediction scores and adjust ACMG classification criteria. Genoox's platform is used in the diagnosis and treatment of genetic disorders and cancer, as well as new drug discovery and family planning, serving markets within the Health Tech & Life Sciences sector.

Strategic signal

In May 2025, Genoox was acquired by Qiagen for up to $80 million, with an initial payment of $70 million in cash and an additional $10 million contingent upon achieving future milestones. This acquisition signifies a significant growth opportunity for Genoox, allowing it to leverage Qiagen's resources and market reach, and highlights the ongoing consolidation within the biomed sector, particularly in genetic analysis.

Company Intelligence Q&A

What was the most significant recent corporate event for Genoox?

In May 2025, Genoox was acquired by Qiagen for up to $80 million, comprising an initial cash payment of $70 million and an additional $10 million contingent on future milestones.

Which investors participated in Genoox's May 2021 funding round?

In May 2021, Genoox secured a funding round led by IN Venture, with participation from Inimiti.

What was Genoox's partnership with Thermo Fisher Scientific about?

In October 2022, Genoox partnered with Thermo Fisher Scientific to automate cytogenetic research data interpretation and reporting using AI.

What was the purpose of Genoox's collaboration with Bionano Genomics in October 2018?

In October 2018, Genoox and Bionano Genomics launched an integrated platform for the identification of structural variants in DNA, combining Bionano's Saphyr system with Genoox technology to speed up genetic diagnoses.

What was the nature of Genoox's partnership with Microsoft Healthcare in October 2018?

In October 2018, Genoox partnered with Microsoft Healthcare to integrate Microsoft Genomics service into its platform, leveraging Microsoft's Azure cloud and AI technologies to advance precision medicine for global customers.